RT Journal Article
T1 Maxillary sinus floor augmentation comparing bovine versus porcine bone xenografts mixed with autogenous bone graft. A split-mouth randomized controlled trial.
A1 Galindo-Moreno, Pablo
A1 Abril-García, Dario
A1 Carrillo-Galvez, Ana Belen
A1 Zurita, Federico
A1 Martín-Morales, Natividad
A1 O'Valle, Francisco
A1 Padial-Molina, Miguel
K1 anorganic bovine bone
K1 bone biomaterial
K1 implant dentistry
K1 maxillary sinus augmentation
K1 porcine bone mineral
AB To compare the effectiveness of two xenografts for maxillary sinus floor augmentation in terms of clinical, radiographical, histologic, and molecular outcomes. A split-mouth randomized clinical trial was conducted at the University of Granada. Ten consecutive patients in need of bilateral two-staged maxillary sinus floor augmentation were included. Each patient received both biomaterials (porcine bone mineral and anorganic bovine bone), which were randomly assigned for bilateral sinus augmentation. The maxillary autogenous bone scraped from the sinus access window was mixed with each xenograft at a 20:80 ratio. After a healing period of 6 months, bone biopsies were collected with a trephine during the implant placement in the regenerated area. Histologic, histomorphometrical, immunohistochemical, and molecular outcomes were analyzed. Clinical and radiographical data throughout the treatment phases were also evaluated. The resulting anatomic features were similar between both groups. After six months of graft consolidation, the graft resorption rates were similar between both biomaterials. The histologic, histomorphometrical, and immunohistochemical results showed no statistical differences between groups. Anorganic bovine bone and porcine bone mineral combined with maxillary autogenous cortical bone show similar biologic and radiologic features in terms of biomaterial resorption, osteoconduction, and osteogenesis when used for maxillary sinus floor augmentation.
YR 2022
FD 2022-03-03
LK http://hdl.handle.net/10668/19929
UL http://hdl.handle.net/10668/19929
LA en
DS RISalud
RD Apr 6, 2025